These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38805864)

  • 1. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells.
    Putra IMR; Lestari IA; Fatimah N; Hanif N; Ujiantari NSO; Putri DDP; Hermawan A
    Comput Biol Chem; 2024 Aug; 111():108084. PubMed ID: 38805864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Potential Target Genes of Borneol in Increasing Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer: Bioinformatics and In Vitro Studies.
    Lestari IA; Putra IMR; Fatimah N; Ujiantari NSO; Putri DDP; Hermawan A
    Asian Pac J Cancer Prev; 2024 May; 25(5):1623-1634. PubMed ID: 38809634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
    Kwon YS; Nam KS; Kim S
    Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab-Resistant HER2
    Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
    Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
    Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
    Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
    Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
    [No Abstract]   [Full Text] [Related]  

  • 7. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
    Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.
    von der Heyde S; Wagner S; Czerny A; Nietert M; Ludewig F; Salinas-Riester G; Arlt D; Beißbarth T
    PLoS One; 2015; 10(2):e0117818. PubMed ID: 25710561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
    Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.
    Sun Z; Zhang C; Wang T; Shi P; Tian X; Guo Y
    J Cancer Res Ther; 2019; 15(4):933-940. PubMed ID: 31436255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
    Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
    Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
    Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.
    Zhang B; Shi J; Shi X; Xu X; Gao L; Li S; Liu M; Gao M; Jin S; Zhou J; Fan D; Wang F; Ji Z; Bian Z; Song Y; Tian W; Zheng Y; Xu L; Li W
    Drug Resist Updat; 2024 May; 74():101068. PubMed ID: 38402670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
    Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
    Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.